uploads/2018/02/Chart-05-3-1.jpg

Sanofi’s Generics and Consumer Healthcare Portfolios in 4Q17

By

Updated

Generics

Sanofi’s (SNY) general medicines and emerging markets portfolios include established prescription products, generic products, and revenues from emerging markets. The company’s generics products reported revenues of 435.0 million euros in 4Q17, a 2.1% decline in operating revenues compared to 4Q16. 

This decline in revenues was driven by lower sales from Europe and emerging markets, substantially offset by strong sales from the US and the rest of the world market in 4Q17. The chart below compares the revenues for generic products and consumer healthcare revenues since 1Q16.

Article continues below advertisement

Consumer healthcare portfolio

Sanofi’s (SNY) consumer healthcare portfolio includes products such as allergy, cough and cold products, digestive products, nutritional products, and pain management products.

Sanofi’s consumer healthcare portfolio reported revenues of 1.2 billion euros in 4Q17, reflecting 51.8% growth in operating revenues compared to 4Q16. This revenue growth was driven by strong sales across all worldwide markets.

The pain management products portfolio reported revenues of 328.0 million euros in 4Q17, reflecting 51.1% growth in operating revenues compared to 4Q16, driven by strong sales across all major markets.

The allergy, cough, and cold products portfolio reported revenues of 293.0 million euros in 4Q17, reflecting 71.3% growth in operating revenues compared to 4Q16. This trend was driven by strong sales Nasacort and Allegra in all major markets outside the US.

The digestive products portfolio reported revenues of 242.0 million euros in 4Q17, reflecting 84.1% growth in operating revenues compared to 4Q16. This trend was driven by strong sales across all worldwide markets.

The nutritional products reported revenues of 156.0 million euros in 4Q17, a 52.3% growth in operating revenues compared to 4Q16, driven by strong sales in all major markets outside the US.

The BLDRS Europe Select ADR ETF (ADRU) holds 21.2% of its total investments in healthcare companies. ADRU holds ~2.6% in Sanofi ADR (SNY), ~2.6% in GlaxoSmithKline ADR (GSK), ~2.5% in AstraZeneca ADR (AZN), and 6.4% in Novartis AG ADR (NVS).

Advertisement

More From Market Realist